Europe
Summit Therapeutics plc announces that it will host a research and development day for investors and media on 7 October 2019 from 8am-12pm EDT in New York City.
Company inaugurates its new production unit for active pharmaceutical ingredients, the cornerstone of Provepharm’s development
Treatment with Erleada plus androgen deprivation therapy resulted in a 25% reduction in the risk of death compared to placebo in prostate cancer patients.
The FDA’s latest approval for Darzalex is based on results from the Phase III CASSIOPEIA trial that showed the addition of Darzalex to VTd before and after ASCT resulted in deeper responses in patients with the blood cancer.
Biocrates Life Sciences AG, the global leader in targeted metabolomics, and Helmholtz Zentrum München, the German Research Center for Environmental Health, enter a new phase of collaboration in their 10-year partnership.
H.E.L. Group Ltd, a global manufacturer of innovative laboratory tools for process optimization, safety and scale-up, announced the appointment of Louise Madden as Chief Executive Officer (CEO).
Bavarian Nordic A/S announced that the U.S. Food and Drug Administration has approved JYNNEOS™ for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
US FDA 510(k) clearance paves the way for an innovative orthopedic product that offers the potential to improve bone apposition and, as a consequence, patient outcomes 1-3
OMO-1 has potential to treat cancer as a monotherapy and in combination with EGFR TKIs for patients becoming resistant to or progressing on treatment
NorthSea Therapeutics B.V. announces dosing of the first patient with icosabutate in a phase 2b dose ranging study.
PRESS RELEASES